The month ahead: May’s remaining events
ASCO is fast approaching, but in the meantime Olema will have an important readout.
ASCO is fast approaching, but in the meantime Olema will have an important readout.
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
Abstract titles reveal some of ASCO’s key datasets.